Close menu




June 27th, 2022 | 12:12 CEST

BrainChip and Palantir with strong rebound - How does BioNTech react?

  • chips
  • Technology
  • Biotechnology
Photo credits: pixabay.com

The correction on the stock markets has been going on for months. Technology stocks, in particular, have been hit hard. Due to the end of the ultra-loose monetary policy and possible larger interest rate steps, even market leaders lost more than 80% of their ground in some cases. Whether interest rate hikes can be implemented as planned in the coming months, on the other hand, appears more than questionable. After all, the spectre of recession is already hovering over the capital markets. Moreover, the historical debt levels of several countries are likely to rule out further interest rate hikes.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: BRAINCHIP HOLDINGS LTD | AU000000BRN8 , PALANTIR TECHNOLOGIES INC | US69608A1088 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BrainChip Holdings - Classic setback offers opportunity

    Unlike Netflix, Zoom or other tech industry giants, the developer of the Akida chip, Australia's BrainChip Holdings, is showing resilience. The share price performance of the emerging IP company, which is the world's first commercial manufacturer of neuromorphic AI chips, has been in the green since the beginning of the year. After starting the year at EUR 0.45, it went up to EUR 1.66 on the back of news related to a cooperation with car giant Mercedes. It was announced that Akida technology would make the "Hey, Mercedes" voice control in the EQXX five to ten times more efficient than conventional voice control. Since then, however, the share has corrected by almost 70% due to the weak market environment. However, a bottom is currently being formed in the EUR 0.60 area. In addition, MACD and RSI are close to a buy signal.

    In the long term, BrainChip's novel AI chip could become the new standard in the semiconductor market. The advantages are that Akida is extremely low-power, high-performance, and promotes the growth of edge AI technology by using neuromorphic architecture, a type of artificial intelligence inspired by the biology of the human brain. BrainChip enables the universal use of efficient edge computing in real-world applications such as connected cars, consumer electronics and the Internet of Things. It is no coincidence that BrainChip has been accepted into chip giant ARM's partner program, enabling research into the next generation of AI solutions.

    Another new partnership is with the inventor of the world's most advanced neuromorphic vision systems, Prophesee. Prophesee's technology is inspired by human vision. It uses a patented sensor design and AI algorithms that mimic the eye and brain to detect what was previously invisible with standard image-based technology. Prophesee's computer vision systems, like Akida, target segments such as autonomous vehicles, industrial automation, IoT, security and surveillance, augmented reality, and virtual reality.

    "We have successfully ported Prophesee's neuromorphic-based camera sensor data to process inferences on Akida with impressive performance," said Anil Mankar, Co-Founder and CDO of BrainChip. "This combination of intelligent vision sensors with Akida's ability to process data with unprecedented efficiency, precision and power savings at the point of capture is a true advancement in AI and provides manufacturers with an immediately actionable solution."

    Palantir with trend reversal

    The stock of data analytics specialist Palantir has been actively working to bottom out in recent weeks. After losing around 88% and marking a new all-time low of USD 6.44 after the quarterly figures were announced, the stock is steadily climbing. Thus, the cracked downward gap at USD 9.48 could also be closed. With regard to the trend-following indicator MACD, a fresh buy signal was generated only on a weekly basis. In addition, the next important resistance is the downward trend formed since the high at currently USD 13.02.

    After the month-long price disaster, analysts from Bank of America are now also speaking out with an initial assessment of the Palantir share. Mariana Perez Mora, an analyst at Bank of America, sees the US software company as a beneficiary of "rapidly growing demand" for artificial intelligence platforms in both commercial and government end markets. The dominant position held by the Palo Alto company should enable CEO Alex Karp's goal of generating at least 30% revenue growth while profits rise. The analyst's initial rating is "buy," with a price target set at USD 13.

    In contrast, the news that the data analytics company is cooperating with Google went more or less under the radar but could become more and more important in the future. According to the Alphabet subsidiary, a long-running partnership will support the digital transformation "in important sectors of the economy". Palantir is making its Foundry platform available via Google Cloud. That should enable users to better analyze and merge their data. The idea that Palantir could become a future takeover candidate for Alphabet does not sound illogical.

    New vaccine - A new wave of buying?

    Despite a correction of around 75%, the market capitalization of the "One Product" company BioNTech is still a whopping EUR 32.57 billion. Although the Mainz-based company is researching cancer vaccines based on mRNA technology, a breakthrough is still years away. The vaccine developers are now achieving this with US cooperation partner Pfizer with regard to the Omicron variant that appeared at the end of last year. The companies announced on Saturday that two adapted vaccine candidates have triggered a strong immune response in the test phase. As a result, approval should follow soon, securing the vaccine subscription for the 2022 winter season. On Tuesday, the FDA will meet with experts to discuss the optimal composition of the fall vaccine.

    "Based on these results, we believe we have developed two very good Omicron-adapted vaccine candidates that elicit a significantly higher immune response to Omicron than what we have seen before," Pfizer CEO Albert Bourla said. BioNTech CEO Ugur Sahin stated, "Omicron has continuously evolving subvariants that displace BA.1 and tend to have increased potential to evade the immune system." From a technical perspective, the stock could hold the critical support at EUR 131. In addition, the indicator situation could brighten up significantly, which means that trading gains are within the realm of possibility, at least in the short term.


    The sharp correction offers interesting entry opportunities in technology stocks such as Palantir and BrainChip. The vaccine producer BioNTech could also see a trend reversal.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST

    70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!

    • Mining
    • Tungsten
    • hightech
    • chemicals
    • Biotechnology

    Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?

    Read

    Commented by Stefan Feulner on July 22nd, 2024 | 06:45 CEST

    Palantir, VCI Global, C3.ai - Beneficiaries of the megatrend

    • AI
    • Fintech
    • Software
    • Technology

    The emergence of ChatGPT brought artificial intelligence into the mainstream. Since then, companies developing various AI services have been springing up like mushrooms. This trend will undoubtedly continue to gain momentum in the future, as various technologies are already too firmly anchored in the economy and society. Despite the current sideways movement on the stock markets, we should continue to keep an eye on the developments of listed players who are likely to benefit from this super cycle in the future.

    Read

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.

    Read